

Sabine ZÃ¶schbauer-MÃ¼ller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5639040/publications.pdf>

Version: 2024-02-01

74
papers

5,209
citations

136885

32
h-index

85498

71
g-index

78
all docs

78
docs citations

78
times ranked

7159
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of temporal muscle thickness on the outcome of radiosurgically treated patients with brain metastases from non-small cell lung cancer. <i>Journal of Neurosurgery</i> , 2022, 137, 999-1005.	0.9	4
2	The impact of COVID-19 on cancer care of outpatients with low socioeconomic status. <i>International Journal of Cancer</i> , 2022, 151, 77-82.	2.3	15
3	Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. <i>Blood</i> , 2021, 137, 1669-1678.	0.6	123
4	Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients. <i>Journal of Neuro-Oncology</i> , 2021, 151, 257-265.	1.4	9
5	Lung Cancer in Austria. <i>Journal of Thoracic Oncology</i> , 2021, 16, 725-733.	0.5	5
6	Neutrophil-to-Lymphocyte Ratio Is Superior to Other Leukocyte-Based Ratios as a Prognostic Predictor in Non-Small Cell Lung Cancer Patients with Radiosurgically Treated Brain Metastases Under Immunotherapy or Targeted Therapy. <i>World Neurosurgery</i> , 2021, 151, e324-e331.	0.7	9
7	Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study. <i>Oncologist</i> , 2020, 25, e1930-e1955.	1.9	20
8	Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases. <i>Cancer</i> , 2020, 126, 4341-4352.	2.0	27
9	Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. <i>Lung Cancer</i> , 2020, 148, 159-165.	0.9	17
10	Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy. <i>Cancers</i> , 2020, 12, 3668.	1.7	13
11	Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma. <i>Thoracic Cancer</i> , 2020, 11, 1979-1988.	0.8	3
12	Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer. <i>Cancers</i> , 2020, 12, 1619.	1.7	24
13	Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation. <i>Frontiers in Oncology</i> , 2020, 10, 593852.	1.3	14
14	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. <i>ESMO Open</i> , 2020, 5, e000880.	2.0	4
15	Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort. <i>Journal of Neuro-Oncology</i> , 2019, 145, 85-95.	1.4	13
16	SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness. <i>Scientific Reports</i> , 2019, 9, 9139.	1.6	34
17	Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer. <i>British Journal of Haematology</i> , 2019, 186, 311-320.	1.2	82
18	DNA methylation of microRNA-coding genes in non-small cell lung cancer patients. <i>Journal of Pathology</i> , 2018, 245, 387-398.	2.1	23

#	ARTICLE	IF	CITATIONS
19	Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery. <i>Journal of Surgical Oncology</i> , 2017, 116, 227-235.	0.8	19
20	SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. <i>Molecular Cancer</i> , 2017, 16, 1.	7.9	196
21	Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients. <i>Oncotarget</i> , 2017, 8, 81250-81260.	0.8	15
22	Lung transplantation in patients with incidental early stage lung cancer – institutional experience of a high volume center. <i>Clinical Transplantation</i> , 2016, 30, 912-917.	0.8	11
23	Management of malignant pleural mesothelioma – part 2: therapeutic approaches. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 618-626.	1.0	8
24	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066.	2.0	17
25	CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. <i>Blood</i> , 2015, 125, 90-101.	0.6	179
26	Epigenetic down-regulation of integrin $\beta 7$ increases migratory potential and confers poor prognosis in malignant pleural mesothelioma. <i>Journal of Pathology</i> , 2015, 237, 203-214.	2.1	28
27	EV11 promotes tumor growth via transcriptional repression of MS4A3. <i>Journal of Hematology and Oncology</i> , 2015, 8, 28.	6.9	25
28	Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. <i>Heart</i> , 2015, 101, 1874-1880.	1.2	181
29	DNA methylation transcriptionally regulates the putative tumor cell growth suppressor <i>ZNF677</i> in non-small cell lung cancers. <i>Oncotarget</i> , 2015, 6, 394-408.	0.8	27
30	Next Generation Sequencing Identifies DNA Methylation Patterns Indicative of Disease Progression in Ph+ CML. <i>Blood</i> , 2014, 124, 4526-4526.	0.6	0
31	A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis. <i>Cancer Cell</i> , 2013, 24, 167-181.	7.7	244
32	ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 80, 278-283.	0.9	59
33	Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. <i>Carcinogenesis</i> , 2013, 34, 513-521.	1.3	67
34	Frequent overexpression of ErbB receptor family members in brain metastases of non-small cell lung cancer patients. <i>Apmis</i> , 2013, 121, 1144-1152.	0.9	15
35	5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. <i>Blood</i> , 2012, 119, 4242-4252.	0.6	41
36	Genome-Wide miRNA Expression Profiling Identifies <i>miR-93</i> and <i>miR-193a</i> as Targets for DNA Methylation in Non-Small Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2012, 18, 1619-1629.	3.2	151

#	ARTICLE	IF	CITATIONS
37	c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6. <i>Blood</i> , 2011, 117, 4065-4075.	0.6	34
38	Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2011, 12, 8530-8538.	1.8	4
39	Lung cancer: From single-gene methylation to methylome profiling. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 95-107.	2.7	99
40	Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 135, 1036-1041.	0.4	45
41	Genome-Wide Transcriptional Response to 5-Aza-2-Deoxycytidine and Trichostatin A in Multiple Myeloma Cells. <i>Cancer Research</i> , 2008, 68, 44-54.	0.4	157
42	Overexpression of the paternally expressed gene <i>10</i> (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2007, 121, 1984-1993.	2.3	67
43	Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence. <i>Molecular Carcinogenesis</i> , 2007, 46, 766-772.	1.3	32
44	JunB is a gatekeeper for B-lymphoid leukemia. <i>Oncogene</i> , 2007, 26, 4863-4871.	2.6	22
45	Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 283-291.	1.1	74
46	NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006, 45, 81-89.	1.8	53
47	Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. <i>Oncogene</i> , 2006, 25, 959-968.	2.6	72
48	Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. <i>Oncogene</i> , 2005, 24, 732-736.	2.6	54
49	Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. <i>Oncogene</i> , 2005, 24, 6249-6255.	2.6	49
50	DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies. <i>Clinical Cancer Research</i> , 2004, 10, 2928-2935.	3.2	59
51	DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. <i>Cancer</i> , 2004, 100, 2598-2606.	2.0	66
52	Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. <i>International Journal of Cancer</i> , 2003, 103, 153-160.	2.3	273
53	Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. <i>International Journal of Cancer</i> , 2003, 107, 612-616.	2.3	132
54	Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. <i>Oncogene</i> , 2003, 22, 1580-1588.	2.6	98

#	ARTICLE	IF	CITATIONS
55	The impact of hemoglobin levels on fatigue and quality of life in cancer patients. <i>Annals of Oncology</i> , 2002, 13, 965-973.	0.6	128
56	Aberrant DNA Methylation in Lung Cancer: Biological and Clinical Implications. <i>Oncologist</i> , 2002, 7, 451-457.	1.9	136
57	Molecular Pathogenesis of Lung Cancer. <i>Annual Review of Physiology</i> , 2002, 64, 681-708.	5.6	169
58	Future developments in the treatment of lung cancer. <i>Lung Cancer</i> , 2002, 38, 81-85.	0.9	6
59	Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. <i>Clinical Cancer Research</i> , 2002, 8, 514-9.	3.2	255
60	Molecular genetic abnormalities in the pathogenesis of human lung cancer. <i>Pathology and Oncology Research</i> , 2001, 7, 6-13.	0.9	65
61	Epigenetic Inactivation of RASSF1A in Lung and Breast Cancers and Malignant Phenotype Suppression. <i>Journal of the National Cancer Institute</i> , 2001, 93, 691-699.	3.0	695
62	Fragile Histidine Triad (FHIT) Gene Abnormalities in Lung Cancer. <i>Clinical Lung Cancer</i> , 2000, 2, 141-145.	1.1	26
63	Promoter Methylation and Silencing of the Retinoic Acid Receptor- α Gene in Lung Carcinomas. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1303-1307.	3.0	334
64	Treatment of small cell lung cancer patients. <i>Annals of Oncology</i> , 1999, 10, 83-91.	0.6	17
65	Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial. <i>European Journal of Cancer</i> , 1998, 34, 1977-1980.	1.3	24
66	MDR1 RNA transcripts do not indicate long-term prognosis in colorectal carcinomas. <i>European Journal of Cancer</i> , 1997, 33, 1516-1518.	1.3	4
67	Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. <i>Leukemia</i> , 1997, 11, 639-643.	3.3	100
68	Adjuvant and Induction Chemotherapies in Non-Small-Cell Lung Cancer. <i>Oncology Research and Treatment</i> , 1996, 19, 221-225.	0.8	0
69	Multidrug Resistance in Leukemias and its Reversal. <i>Leukemia and Lymphoma</i> , 1996, 23, 451-458.	0.6	32
70	MDR1 Gene Expression in Lymphocytes of Patients with Renal Transplants. <i>Nephron</i> , 1995, 69, 277-280.	0.9	26
71	Dexverapamil as resistance modifier in acute myeloid leukaemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995, 121, R21-R24.	1.2	9
72	MDR1 Gene Expression in Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1994, 13, 333-338.	0.6	11

#	ARTICLE	IF	CITATIONS
73	MDR1 gene expression in primary colorectal carcinomas. <i>British Journal of Cancer</i> , 1993, 68, 691-694.	2.9	29
74	MDR1 RNA Expression as a Prognostic Factor in Acute Myeloid Leukemia: An Update. <i>Leukemia and Lymphoma</i> , 1993, 12, 91-94.	0.6	17